Literature DB >> 6105934

Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.

J Fabre, H M Fox, P Dayer, L Balant.   

Abstract

Adjustment of dosage of a renally excreted drug (or active metabolite) for patients with severe renal failure still causes some difficulties. It is therefore helpful to select, within a given therapeutic group of drugs, a compound that is particularly safe and easy to use and, if possible, does not require adjustment of dosage. This is 'the drug of choice for renal patients'. Such a drug would ideally meet the following pharmacokinetic criteria: normal urinary excretion less than 30% of the administered dose, predominant biliary and intestinal removal, disposition essentially unaffected by parameters likely to be modified in renal failure (e.g. changes in serum proteins or fluid compartments: receptor sensitivity, etc), and pharmacokinetics not complicated by the formation of active or toxic metabolites that depend on urinary elimination. Above all, the drug should have a wide therapeutic margin and must be free of nephrotoxicity. Examples of drugs of choice for patients with impaired renal function are given for some important therapeutic groups and special emphasis is placed on antibiotics and beta-adrenoceptor blocking agents.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6105934     DOI: 10.2165/00003088-198005050-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  143 in total

Review 1.  [Pharmacokinetic perturbations in kidney failure. Anomalies of metabolites and tissue diffusion (author's transl)].

Authors:  J Fabre; L Balant; M Rudhardt; P Blanchard
Journal:  Nouv Presse Med       Date:  1979 Aug 25-Sep 3

2.  A study of practolol elimination in all grades of chronic renal failure.

Authors:  C M Kaye; C R Kumana; D A Franklin; L R Baker
Journal:  Int J Clin Pharmacol Biopharm       Date:  1975-07

3.  CEPHALOTHIN SERUM LEVELS IN THE AZOTEMIC PATIENT.

Authors:  S A KABINS; S COHEN
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1964

4.  Pharmacokinetics of oral propranolol in chronic renal disease.

Authors:  D T Lowenthal; W A Briggs; T P Gibson; H Nelson; W J Cirksena
Journal:  Clin Pharmacol Ther       Date:  1974-11       Impact factor: 6.875

5.  Acute renal failure after rifampicin.

Authors:  D Kleinknecht; J C Homberg; G Decroix
Journal:  Lancet       Date:  1972-06-03       Impact factor: 79.321

6.  Pharmacodynamics of practolol in chronic renal failure.

Authors:  J B Eastwood; J R Curtis; R B Smith
Journal:  Br Med J       Date:  1973-11-10

7.  Potentially serious side effects of high-dose twice-weekly rifampicin.

Authors:  G Poole; P Stradling; S Worlledge
Journal:  Br Med J       Date:  1971-08-07

8.  Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency.

Authors:  G Humbert; J P Fillastre; A Leroy; M Godin; C Van Winzum
Journal:  Rev Infect Dis       Date:  1979 Jan-Feb

9.  Beta-adrenergic receptor blockade and renal function.

Authors:  D J Warren
Journal:  Am Heart J       Date:  1976-02       Impact factor: 4.749

10.  Pharmacokinetics of netilmicin in the presence of normal or impaired renal function.

Authors:  G Humbert; A Leroy; J P Fillastre; G Oksenhendler
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

View more
  6 in total

Review 1.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

2.  Clinical pharmacology. Elimination of drugs.

Authors:  H E Barber; J C Petrie
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-07

3.  The metabolic disposition of flucloxacillin in patients with impaired kidney function.

Authors:  H H Thijssen; J Wolters
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 4.  Pharmacokinetics of drug overdose.

Authors:  J Rosenberg; N L Benowitz; S Pond
Journal:  Clin Pharmacokinet       Date:  1981 May-Jun       Impact factor: 6.447

5.  Pharmacokinetics of ranitidine in patients with chronic renal failure.

Authors:  M L McFadyen; P I Folb; R Miller; G R Keeton; I N Marks
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.